C1071006 (NDMM) Été 2024
An open-label, 2-arm, multicenter, randomized phase 3 study to evaluate the efficacy and safety of elranatamab (pf-06863135) + daratumumab + lenalidomide versus daratumumab + lenal
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
[English] A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma [English] Study CC-99712-MM-001 is an open-label, Phase